Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.14094 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2024. Verfasst von Rong Shao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical Pharmacology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Healthy Volunteers, Receptors, Opioid, kappa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Major Science and Technology Project of China, Sichuan Haisco Pharmaceutical Co., Ltd., National Major Science and Technology Projects of China.
Abstract (Originalsprache)
HSK21542 injection is a new peripheral kappa opioid receptor (KOR) agonist. To evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics, this study was conducted in healthy volunteers, consisting of two parts: a single ascending dose (0.2–3.375 μg/kg, 15‐min infusion) and different infusion durations (0.2 and 1 μg/kg, 2‐ or 15‐min infusion). The area under the plasma concentration‐time curve (AUC) and peak concentration (C max ) of HSK21542 were dose‐linear among 0.2–3.375 μg/kg. After intravenous injection, HSK21542 was rapidly eliminated with a half‐life (t 1/2 ) of 1.5 h, and the majority (48.02%) of the dose was excreted unchanged in urine. Pharmacodynamic results showed that HSK21542 increased prolactin release and reached a peak at 1–2 h after administration but had no significant effect on vasopressin levels. There was a brief increase in urine volume within the initial 2 h after administration. HSK21542 was well tolerated; most of the adverse effects (AEs) in the trial group were grade 1, and only 2 cases (4.0%) were grade 2. The main AE was paresthesia, which appeared in 42% (21/50) in the trial group. No serious adverse event (SAE) was observed. No subject withdrew early due to AEs. These results suggest that HSK21542 may be a potential treatment for pain and pruritic conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Clinical Pharmacology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Anesthesiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Sichuan Haisco Pharmaceutical Co., Ltd., Chengdu, China.
ORCID-Profile: Rong Shao, Yi-Chao Xu
Förderung
- National Major Science and Technology Project of China
- Sichuan Haisco Pharmaceutical Co., Ltd.
- National Major Science and Technology Projects of China
Zitieren
APA
Shao, R., Wang, H. Y., Ruan, Z. R., Jiang, B., Yang, D. D., Hu, Y., Xu, Y. C., Yang, J. T., Gao, W., Zhao, W. Y., Yan, M., & Lou, H. (2024). Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14094
Vancouver
Shao R, Wang HY, Ruan ZR, Jiang B, Yang DD, Hu Y, et al. Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14094
BibTeX
@article{Shao2024,
author = {Shao, Rong and Wang, Hai-Ying and Ruan, Zou-Rong and Jiang, Bo and Yang, Dan-Dan and Hu, Yin and Xu, Yi-Chao and Yang, Jin-Ting and Gao, Wei and Zhao, Wan-Yun and Yan, Min and Lou, Honggang},
title = {Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.14094}
}
EUVIMED